Immunosuppressive Therapy in Myelodysplastic Syndromes Is Still Alive

Publisher： Karger

E-ISSN： 1421-9662|134|3|135-137

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.3, 2015-04, pp. : 135-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Danazol Therapy for Thrombocytopenia in Patients with Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 107, Iss. 4, 2002-05 ,pp. : 234-236

Karger

Access to resources Recommend Favorite

Diagnosis and Therapy of Myelodysplastic Syndromes in Germany: A Retrospective Multicenter Analysis

By  

Oncology Research and Treatment, Vol. 35, Iss. 6, 2012-05 ,pp. : 350-356

Karger

Access to resources Recommend Favorite

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 6, 2015-06 ,pp. : 463-463

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 313-320

John Wiley & Sons Inc

Access to resources Recommend Favorite

Decitabine in myelodysplastic syndromes

By Jabbour Elias   Kantarjian Hagop M   Garcia-Manero Guillermo   Issa Jean-Pierre J  

Therapy, Vol. 2, Iss. 6, 2005-11 ,pp. : 835-842

Future Medicine

Access to resources Recommend Favorite